In this study we aimed (a) to ascertain whether a relationship exists between different treatment programmes and settings for personality disorder and patient characteristics; (b) to give an indication of treatment effects in three personality disordered populations admitted to different treatment contexts; and (c) to compare costs in relation to outcomes. We collected and compared three samples from one in-patient site (Cassel in England) and two day hospitals (Halliwick in England and Ulleval in Norway) on a number of demographic, diagnostic and other key clinical variables. Outcome in the areas of symptom severity (Symptom Checklist-90-R) and social adaptation (Social Adjustment Scale) was evaluated by comparing admission with discharge scores. Treatment costs for each sample were also estimated and compared. Significant differences were found on most baseline variables across the three sites. In general with regard to severity of psychopathology, the Halliwick sample was the most disturbed, Ulleval the least, with Cassel somewhat in between. No significant differences in improvement were found among the three sites, but treatment costs were considerably higher at Cassel than in the two day centres. The differences found in the three samples bear no clear relationship to context of treatment. These results suggest that referral of personality disorder for in-patient or day hospital treatment is less influenced by severity of problem than had previously been supposed and may depend more on availability of treatment facility.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1348/147608302321151899 | DOI Listing |
J Affect Disord
January 2025
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. Electronic address:
Background And Objective: To determine whether there is disproportionate reporting of hepatobiliary disorders in the United States (US) FDA Adverse Event Reporting System (FAERS) for individuals prescribed ketamine or esketamine.
Design: We identified Medical Dictionary for Regulatory Activities (MedDRA) terms in the FAERS related to hepatobiliary disorders.
Main Measures: Formulations of ketamine and esketamine were evaluated for the proportionality of reporting for each hepatobiliary disorder parameter using the reporting odds ratio (ROR).
Cephalalgia
January 2025
Functional Pharmacology and Neuroscience Unit, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Background: Individuals with autism spectrum disorder (ASD) experience a wide array of neurological, psychiatric and medical comorbidities, yet little attention has been given to the potential link between ASD and migraine, one of the most prevalent neurological disorders worldwide. This study aimed to investigate whether a genetic predisposition for ASD is linked to migraine and its major subtypes, with and without aura. Additionally, potential moderator and mediators of the association between ASD and migraine were explored.
View Article and Find Full Text PDFAlthough behavioral avoidance is observed among those with heightened contamination concerns, the extent to which such avoidance is best predicted by state and/or trait characteristics is unclear. Furthermore, while disgust proneness is a disease-specific trait that has been shown to predict avoidance among those with symptoms of contamination-based obsessive-compulsive disorder (OCD), it is unclear if other disease-specific traits may also serve a similar function. In the present study, contamination-fearful participants (N = 89) first completed self-report measures of disease-specific (disgust proneness, health anxiety, perceived vulnerability to disease) and disease-nonspecific (intolerance of uncertainty, trait anxiety) traits.
View Article and Find Full Text PDFPsychiatry Res
January 2025
Department of Psychiatry, University Medical Center Groningen, Groningen, the Netherlands.
Accumulating evidence supports the efficacy of (es)ketamine in the treatment of major depressive disorder (MDD), particularly treatment-resistant depression (TRD). Yet around 50% of the individuals with TRD do not respond to (es)ketamine. Elucidating predictors of response and remission could improve treatment outcomes at the individual level by defining subpopulations that are most likely to benefit from (es)ketamine.
View Article and Find Full Text PDFJAMA Netw Open
January 2025
Millennium Nucleus to Improve the Mental Health of Adolescents and Youths (IMHAY), Santiago, Chile.
Importance: Mental health stigma is a considerable barrier to help-seeking among young people.
Objective: To systematically review and meta-analyze randomized clinical trials (RCTs) of interventions aimed at reducing mental health stigma in young people.
Data Sources: Comprehensive searches were conducted in the CENTRAL, CINAHL, Embase, PubMed, and PsycINFO databases from inception to February 27, 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!